SMMT Quote, Financials, Valuation and Earnings

Exelixis, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 40.85%. Summit Therapeutics, Inc.'s return on equity of -292.79% beat Exelixis, Inc.'s return on equity of 36.46%.

Summit Therapeutics, Inc. has a consensus price target of $31.72, signalling upside risk potential of 91.13%. On the other hand Exelixis, Inc. has an analysts' consensus of $47.17 which suggests that it could grow by 7.05%. Given that Summit Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Exelixis, Inc..

Summit Therapeutics, Inc. has a beta of -1.429, which suggesting that the stock is 242.925% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $598.7M. Summit Therapeutics, Inc.'s net income of -$219.2M is lower than Exelixis, Inc.'s net income of $244.5M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 15.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 5.35x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -124.5%. Summit Therapeutics, Inc.'s return on equity of -292.79% beat Insmed, Inc.'s return on equity of -192.35%.

Summit Therapeutics, Inc. has a consensus price target of $31.72, signalling upside risk potential of 91.13%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 42.32%. Given that Summit Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Insmed, Inc..

Summit Therapeutics, Inc. has a beta of -1.429, which suggesting that the stock is 242.925% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.112%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Summit Therapeutics, Inc.'s net income of -$219.2M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 48.98x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 34.4%. Summit Therapeutics, Inc.'s return on equity of -292.79% beat Eli Lilly & Co.'s return on equity of 104.39%.

Summit Therapeutics, Inc. has a consensus price target of $31.72, signalling upside risk potential of 91.13%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 15.43%. Given that Summit Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Summit Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Summit Therapeutics, Inc. has a beta of -1.429, which suggesting that the stock is 242.925% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.73 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Summit Therapeutics, Inc.'s net income of -$219.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 14.70x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of --. Summit Therapeutics, Inc.'s return on equity of -292.79% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Summit Therapeutics, Inc. has a consensus price target of $31.72, signalling upside risk potential of 91.13%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $130.05 which suggests that it could grow by 27.32%. Given that Summit Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..

Summit Therapeutics, Inc. has a beta of -1.429, which suggesting that the stock is 242.925% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Summit Therapeutics, Inc.'s net income of -$219.2M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.